SCHEMBL6286873

SCHEMBL6286873

Cc1ccccc1S(=O)(=O)NC(=O)C(C)c1cccc(C(=O)c2ccccc2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.63
CYP3A4 P08684 2/20 0.63
CYP1A2 P05177 1/20 0.63
CYP2D6 P10635 1/20 0.63
CYP2C9 P11712 1/20 0.63
CYP2C19 P33261 1/20 0.63
NPSR1 Q6W5P4 1/20 0.59
MAPT P10636 5/20 0.57
LMNA P02545 3/20 0.57
ALDH1A1 P00352 3/20 0.57
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
SMN1; SMN2 Q16637 3/20 0.56
PTGS1 P23219 3/20 0.56
PTGS2 P35354 3/20 0.56
CXCR1 P25024 2/20 0.56
CXCR2 P25025 2/20 0.56
RECQL P46063 1/20 0.56
KDM4E B2RXH2 1/20 0.56
HPGD P15428 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1883565 0.82 MAPT (0.64) HTTCYP3A4CYP1A2CYP2D6CYP2C9
SCHEMBL1883564 0.82 MAPT (0.64) HTTCYP3A4CYP1A2CYP2D6CYP2C9
SCHEMBL15486527 0.80 MAPT (0.61) HTTCYP3A4CYP1A2CYP2D6CYP2C9
SCHEMBL7011096 0.79 CA12 (0.61) HTTCYP3A4CYP1A2CYP2D6CYP2C9
SCHEMBL6277561 0.78 MAPT (0.58) HTTCYP3A4CYP1A2CYP2D6CYP2C9
SCHEMBL6319806 0.78 MAPT (0.58) HTTCYP3A4CYP1A2CYP2D6CYP2C9
SCHEMBL6283316 0.77 CA12 (0.53) HTTCYP3A4CYP1A2CYP2D6CYP2C9
SCHEMBL7011092 0.76 CA12 (0.57) HTTCYP3A4CYP1A2CYP2D6CYP2C9
SCHEMBL6315710 0.76 CA12 (0.57) HTTCYP3A4CYP1A2CYP2D6CYP2C9
SCHEMBL12837394 0.75 MAPT (0.54) HTTCYP3A4CYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887903-B1 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them DOMPE S.P.A. (IT) 2005-05-03 US disclosed
US-6881755-B2 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them Dompé S.p.A. (IT) 2005-04-19 US disclosed
US-20030216392-A1 N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them DOMPE S.P.A. 2003-11-20 US disclosed
EP-1123276-B1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM DOMPE SPA (IT) 2003-01-08 EP disclosed
EP-1123276-A1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM Dompe' S.P.A. (IT) 2001-08-16 EP disclosed
WO-2000024710-A1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM DOMPE' S.P.A. (IT) 2000-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216392-A1 N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them ELANE, MPO, FPR1 HTT 4383/4885CYP3A4 1110/4885CYP1A2 370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.